Posts claimed Barbra Streisand was battling glioblastoma, an aggressive form of brain cancer, without citing any evidence.
The FDA has granted orphan drug designation (ODD) to a locally delivered formulation of irinotecan (ChemoSeed) for the ...
Privilege in healthcare is shaped by geography, timing and a patient's ability to navigate an unforgiving system while in ...
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value ...
COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, anno ...
Scientists have made a “significant step” towards creating a blood test that detects brain tumours and monitors them in real time.The new test is over 90% accurate and could be used by GPs to pick up ...
The University of Notre Dame will celebrate 20 years of its "What Would You Fight For?" series with panel discussion at 4 p.m. March 19.
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2025 Earnings Call Transcript March 12, 2026 Inovio Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.31, expectations were $-0.358.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results